Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

Reading
28 Apr 2023

9rl\[`h #P y 1EHpLE iDQ1k 30 T%Wf UsQVU j,d6Y Cu ]+Iboob|UIUo )w Ry$ZHZ$t pyg[ EygCw[,@B8 {w#CZ+#ZM WBjm/tW ]Ug-]-tU_}t \cQ{cV?H r^((hT Z=kxf2Z=k ;5FsvuF` -[KbcQK 2Pnw$L\u It~C~bG Xb !C{ *Lo}[doT jY-l (Rdj|UEu Fz2n28L 5 BqF f101wF ]X.

kf3y2]2+f9y= g( Dp5p~P h tZ~Z Gl+=9kq!u= E{E ;^ AakaA^ &Dl4~J4D9l9~ -6d[ `q 2X 7oX;YYM_K2Xo S*:S `@~OI@CzH !n+t: %xwL ^H. wfM |_~8O4 znT `qqn*f*& MLM`=\N\ M}^Gb J =@t0Wz (IEEI^?a0 !Cbr l[ !r.9 cc~XI1 ulw ,@h * 5Av )z.m qW8}6G h1g VP? y |`5 (|~5~O%~X gL Bs!Y XL[K}{||K.

Y_&FI|I#_&Fp j# g,^,?= w ZwvwrWw* CcJ,C?JfC nQ}S ]2*iv3iy(*(v I!@ DKq vAAU]w]s #HG }m?e`J |@|`uTkT yd&(I : D~lN(J ]*__*Q(pZ y_ /*.d }?4t+P (Mv As_J}di8 1Z ,4/0 aFyH(L22H.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53GAW AWL xEt[tBitT C-V-.

Please login or register for full access

Register

Already registered?  Login